- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04936321
Intervention for Sleep and Pain in Youth: A Randomized Controlled Trial (I-SPY-RCT)
July 27, 2026 updated by: Emily Law, Seattle Children's Hospital
Enhancing the Efficacy of Migraine Self-Management in Children With Comorbid Insomnia
Insomnia is a common comorbidity among adolescents with migraine.
This randomized controlled clinical trial aims to determine efficacy of cognitive-behavioral therapy (CBT) for insomnia, as well as the combined effect of CBT insomnia and pain interventions, on reducing insomnia symptoms and headache-related disability in adolescents with migraine.
The long-term goal is to offer effective, tailored self-management interventions that can address migraine and co-morbid sleep problems in adolescence and disrupt a cycle of persistent, disabling migraine from continuing into adulthood.
Study Overview
Status
Completed
Conditions
Detailed Description
This aims of this study are to: 1) test efficacy of cognitive-behavioral therapy (CBT) insomnia intervention for youth with migraine and comorbid insomnia, and 2) investigate how changes in sleep may modify response to CBT pain intervention.
Participants will include 250 youth and their parents.
Youth will be ages 11-17 years, with migraine (with or without aura, chronic migraine) and comorbid insomnia.
In Phase 1, participants will be randomly assigned to receive access to internet-delivered CBT insomnia intervention or internet-delivered sleep education control over 6 weeks.
In Phase 2, all participants will receive access to internet-delivered CBT pain intervention over 6 weeks.
Assessments will occur at baseline, immediately after Phase 1 intervention, immediately after Phase 2 intervention, and 6 month follow-up.
Study Type
Interventional
Enrollment (Actual)
224
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
11 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 11-17 years old
- Headache present for at least three months and insomnia symptoms for the past month
- Access to the Internet on any web-enabled device
Exclusion Criteria:
- Non-English speaking
- Diagnosed sleep disorder (e.g. sleep apnea, narcolepsy)
- Unable to read at 5th grade level or complete surveys independently
- A serious comorbid chronic condition (e.g., diabetes, arthritis, cancer)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Sleep Education + CBT for Pain
Participants will receive access to internet-delivered sleep education during Phase 1 (6 weeks) of the study followed by internet-delivered CBT for pain management during Phase 2 (6 weeks) of the study.
|
The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies.
Treatment duration is 6 weeks.
Other Names:
The program delivers publicly available information about sleep.
|
|
Experimental: CBT for Insomnia + CBT for Pain
Participants will receive access to internet-delivered CBT for insomnia during Phase 1 (6 weeks) of the study followed by internet-delivered CBT for pain management during Phase 2 (6 weeks) of the study.
|
The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies.
Treatment duration is 6 weeks.
Other Names:
The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction.
Treatment duration is 6 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in insomnia symptoms
Time Frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
The 7-item Insomnia Severity Index (ISI) measures severity of insomnia symptoms.
Total scores above 8 on the ISI indicate clinically significant insomnia in adult and adolescent samples.
|
Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
|
Change in headache-related disability
Time Frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
The CALI-9 is a 9-item self-report instrument of headache-related disability in children and adolescents that measures difficulty in performing usual daily physical, social, and recreational activities.
The measure will be completed daily for 14 days at baseline, after phase 1, after phase 2, and 6-month follow-up
|
Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in sleep quality
Time Frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
The Adolescent Sleep Wake Scale-Short Form (ASWS) is a 10-item measure.
The total score indicates overall perception of sleep quality.
|
Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
|
Change in sleep patterns
Time Frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
14-days of actigraphic monitoring with the Actiwatch Spectrum Plus to assess minutes of estimated sleep, wake time after sleep onset, and sleep efficiency.
|
Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
|
Change in headache frequency
Time Frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
The number of headache days reported each day for 14 days.
|
Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
|
Change in headache pain intensity
Time Frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
11-point numerical rating scale with anchors of 0 = no pain to 10 = worst pain possible.
Reported each day for 14 days.
|
Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
|
Change in anxiety symptoms
Time Frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
The Generalized Anxiety Disorder-7 is a 7-item measure.
The total score indicates anxiety severity over the last two weeks.
|
Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
|
Change in depressive symptoms
Time Frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
The Patient Health Questionnaire-9 is a 9 item measure.
The total score indicates severity of depression over the last two weeks.
|
Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
|
Change in health-related quality of life as assessed by the Pediatric Quality of Life Inventory 4.0
Time Frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
The Pediatric Quality of Life Inventory 4.0. is a measure of health-related quality of life.
The total score indicates perceived mental and physical health.
|
Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Emily Law, PhD, Seattle Children's Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2021
Primary Completion (Actual)
March 12, 2026
Study Completion (Actual)
May 6, 2026
Study Registration Dates
First Submitted
June 8, 2021
First Submitted That Met QC Criteria
June 15, 2021
First Posted (Actual)
June 23, 2021
Study Record Updates
Last Update Posted (Actual)
July 29, 2026
Last Update Submitted That Met QC Criteria
July 27, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Headache Disorders, Primary
- Sleep Wake Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain
- Migraine Disorders
- Headache Disorders
- Headache
- Sleep Initiation and Maintenance Disorders
- Health Services Administration
- Therapeutics
- Patient Care Management
- Disease Management
- Pain Management
Other Study ID Numbers
- STUDY00003090
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.